Syndax Pharmaceuticals' Entinostat In Combination Shows Activity In Breast Cancer

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer...

More... (http://mnt.to/f/3NXG)